Half-year report on the DBV Technologies liquidity contract
AMF REGULATED INFORMATION
Montrouge, France, August 6, 2021
Half-year report on the DBV Technologies liquidity contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Exchange: DBVT), a clinical-stage biopharmaceutical company, today published the half-yearly report on its liquidity contract with ODDO BHF.
As of June 30, 2021, the following assets were included in the liquidity account:
- 77,875 DBV Technologies shares;
- € 480,481.63
When the liquidity contract was signed in July 2018, the following resources appeared in the liquidity account:
- 24,313 ordinary DBV Technologies shares;
- € 682,454.94.
Number of transactions executed during the second half of 2020:
- Purchase: 1,105
- Sale: 1,146
Over the same period, the volumes traded represented:
- 461,457 DBV Technologies ordinary shares repurchased for € 4,297,042.80
- 495,884 DBV Technologies ordinary shares sold for € 4,548,434.80
About DBV Technologies
DBV Technologies is developing Viaskin ™, an exclusive investigative technological platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT ™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is committed to safely transforming the care of patients with food allergies. DBV’s food allergy programs include ongoing clinical trials with Viaskin Peanut. DBV Technologies is headquartered in Montrouge, France, and its North American operations in Summit, New Jersey. The Company’s ordinary shares are traded on the B segment of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADS (each representing half of a share Ordinary) are traded on the Nasdaq Global Select Market (symbol: DBVT).